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Summary
Interleukin 5 (1175) has been suggested to be involved in the growth and differentiation of B
cells and eosinophils. Especially, Ly-1+ B cells, which have been considered to produce
autoantibodies, are selectively developed by this lymphokine in long-term bone marrow culture.
To envisage the possible engagementof IL5 in the development of these cells in vivo, transgenic
mice carrying the mouse IL5 gene ligated with a metallothionein promoter were generated.
Transgenic mice carrying the 1175 gene exhibited elevated levels of 11,5 in the serum and an increase
in the levels of serum IgM and IgA. A massive eosinophilia in peripheral blood, bone marrow,
and spleen, and an infiltration ofmuscle and liver with eosinophils, were observed. When cadmium-
containing saline was injected intraperitoneally into transgenic mice, IM production was augmented
about five times within 24 h, and a distinctive Ly-1 + B cell population became apparent in the
spleen after 5 d. 1175 receptors were detected on those cells by monoclonal antibodies against
IL-5 receptors. Another interesting finding in these transgenic mice was an increase in polyreactive
anti-DNA antibodies of IgM class. It is suggested, therefore, that aberrant expression of the
IL5 gene may induce accumulation of Ly-1+ B cells and eosinophils. Furthermore, this IL5
transgenic mouse can be a model mouse for eosinophilia, and we can determine the role of IL5
in the differentiation of Ly-1 + B cells and eosinophils by using this mouse.
T
he study of IL5'originated in the search for one of the
B cell growth and differentiation factors, named T
cell-replacing factor (TRF),1 that induces antigen-stimulated
B cells to differentiate into plasma cells (1-3) or growth of
BCLi B cell tumor (BCGFII) (4) . On the other hand, eo-
sinophil differentiation factor (5) has been known as a diffusible
factor from thoracic duct lymphocytes ofparasite-infected rats
(6). The cDNA cloning (7-9) and the mAb against IIr5 (10)
enabled us to identify this molecule as a cytokine that has
been known to induce activated B cells into IgM- and IgA
secreting cells (7-12), to maintain the growth ofB cells (13-15),
to induce the expression of the IL2R a chain on the surface
of B and T lymphocytes (16-18), to stimulate growth and
differentiation ofeosinophils (5, 9, 19, 20), and to play a major
'Abbreviations used in thispaper. mmTi, mouse metallothionein promoter;
PE-Av, phycoerythrin-conjugated streptoavidin; TNP, 2,4,6-trinitrophenyl
hapten; TRF, T cell-replacing factor.
role in T cell-dependent antibody production (21, 22). 11,5
is an inducible hormone (23) produced mainly by T cells after
antigen stimulation such as Mycobacterium tuberculosis or Tox-
ocara canis (24, 25).
We also observed in an in vitro bone marrow culture that
11,5 could work as growth and differentiation factor for eo-
sinophils and that Ly-1+ B lineage cells were selectively
maintained in the presence of 11,5 (26). Ly-1 + B cells are a
minor population of B lineage cells that are known to pro-
duce a restricted immunoglobulin repertoire including au-
toantibodies (27, 28). It is not clear, however, whether
Ly-1 + B cells are involved in the production of autoanti-
bodies in vivo. It is important, therefore, to evaluate whether
or not autoantibodies areproduced according to the increased
incidence of Ly-1+ B cells by continuous exposure of hema-
topoietic stem cells to IM. We describe here the production
of transgenic mice by introducing the mouse IIr5 cDNA
ligated to mouse metallothionein promoter (mMTI). A mas-
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spleen were observed in the resulting transgenic mice. The
production of polyreactive IgM antibody against single-
stranded (ss) and double-stranded (ds)DNAwas seen in 11,5
transgenic mice.
Materials and Methods
Construction of the mMTI--IL5 Gene and Production of Transgenic
Mice. EcoRI-Bg1IImMTIpromoter fragment frompdBPVmMT
neo vector (a generous gift from Dr. P . Howley, NIH, Bethesda,
MD) (29) was used to express murine IL5 (mIIr5) cDNA. The
3' untranslated region ofmIL5 cDNA that contains an AU-rich
sequence was removed. The structure of the mMTI-IL5 gene is
shown in Fig. 1 . The Xmnl-Nrul fragment of this construct was
microinjected into the pronuclei of fertilized eggs of C3H/HeN
mice as described (30) . For screening of transgenic mice, mouse
tailDNAwas isolated according to the procedures described previ-
ously (31) and digested with BamHI . DigestedDNAwas analyzed
as describedby Southern (32) . The 11,5 probe used was the 461-bp
Sacl-Accl fragment of pSP6K-nTRF23 (24) .
Assessment of11,5 Activity by BCGFII Assay.
￿
11,5 activities of
rIL5 were assessed by DNA synthesis with the use ofT88-M cells
(BCGFII assay) (23, 26), andwere expressed in nanograms per mil-
liliter. IL5-dependent T88-M cells were inoculated in a 96-well mi-
crotiter plate at a concentration of 1.5 x 104/0.2 ml/well with
serially diluted samples to be tested . Uptake of ['H]thymidine by
these cells, which hadbeen pulsed with 0.2 P,Ci/well during the
last 6 h of a48-h culture, was determined in a liquid scintillation
counter.DNA synthesis was determined by means of [3H]thymi-
dine incorporation. In each assay, affinity-purified rIL5 was also
included as a standard (23) .
ELISA to Detect IL5.
￿
Anti-IL5 mAb NC17 (100 ttg/ml) was
coated onto polyvinyl plate wells (Micro Test III; 3911; Becton Dick-
inson& Co ., Oxnard, CA), and the nonspecific binding sites were
blocked with PBS (10 mM phosphate, 140 mM NaCl, pH 7.2)
containing 2% BSA. Samples were then applied to the wells and
incubated overnight at room temperature . Afterwashing the wells
with PBS containing 0.05% Tween 20, polyclonal rabbit anti-mu-
rine IL-5 antibodies were added to the wells, followed by a 4-h in-
cubation at room temperature.Then, horseradish peroxidase-cou-
pled goat anti-rabbit Ig (Bio-Rad Laboratories, Richmond, CA)
and 2,2'-azino-di (3-ethyl)benzthiazoline sulfonic acid (ABTS) were
used as acoloring system according to the manufacturer's recom-
mendation . OD was read at 405 nm . Standard curvewas obtained
by using purified rIL5 .
Northern Blot Analysis.
￿
TotalRNAs were isolated by the guani-
dine isothiocyanate method (33) . 20 Wg of totalRNA from each
sample was analyzed by Northern blotting as described (34) .
"P-labeled SacI-Accl fragment of 11,5 cDNA (prepared by using
Oligolabeling kit from Pharmacia Fine Chemicals, Piscataway, NJ)
was used as a probe. Results were shown through Bio Analyzer
100 (Fuji Photo Film, Tokyo, Japan) .
Fluorescence-activated Cell Sorter (FRCS®) Analysis.
￿
Total spleen
cells, peritoneal exudate cells, and bone marrow cells from trans-
genic mice and age-matched control mice were prepared after
removing red blood cells . They (106) were stained with bio-
tinylated rat mAb against CD5 (Ly-1 .53.7.3, rat IgG2a; Becton-
Dickinson & Co., Mountain View, CA) plus phycoerythrin-
conjugated streptoavidin (PE-Av ; Becton Dickinson&Co .) and
counterstained with anti-B220 (6B2, a kind gift from Dr. I .
Weissman, Stanford University, Palo Alto, CA)followed by FITC-
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conjugatedmAb against rat anti-u (MAR18.5 ; kindly provided by
Dr. J . Kappler, National Jewish Hospital, Denver, CO), or FITC-
coupled IgM (LO.MM9 ; Serotec, Oxford, England) . In the case
of H7 (a mAb that recognizes ligand-binding moiety of I1.5R,
[35-39]) vs. Ly-1 (CD5), cells were stained with FITC-conjugated
anti-Ly-1 at first and then counterstained with biotinylated F(ab)' Z
fragments of H7 (rat IgG2a) and PE-Av. Negative controls were
cells incubated with PE-Av or FITC MAR18.5 . To mask the
nonspecific binding sites, cells were preincubated with a 20-fold
excess amount of subclass-matched control antibodies (rat anti-Lyt-2,
56-6.72; rat IgG2a) for 15 min at4°Cbefore staining.Other general
procedures were performed as described (26) . These cells were then
suspended in PBS containing 3% FCS and 0.05% NaN3 and ana-
lyzed on a FACScan (Becton Dickinson & Co.) .
Titration of Serum Immunoglobulin Levels and Autoantibodies.
Serum immunoglobulin levels were assessed by ELISA by using
isotype-specific antibodies as described (12) . Results were expressed
as micrograms per milliliter serum. Anti-ssDNA andanti-dsDNA
antibodies were also measured by ELISA as described previously
(40) with a slight modification . Briefly, ssDNA ordsDNA purified
from calf thymus DNA, according to the method of Stollar and
Papalian (41) wascoated on 96-well assayplates (3921; Becton Dick-
inson & Co .) that had been precoated with poly-L-lysine. These
plates were blocked with TBS (25mM Tris, 140mM NaCl, pH
7.4) containing 5% FCS and0.05% Tween 20 . Sera were diluted
1:100 with TBS containing 5% FCS . After each incubation, the
plates were washed withTBScontaining 0.05% Tween 20 . Bound
antibodieswere detectedwith alkaline phosphatase-conjugated rabbit
anti-mouse IgG (Pel-Freez Biologicals, Rogers, AZ) or with alka-
line phosphatase-conjugated rabbit anti-mouse IgM (Zymed,South
San Francisco, CA) . The substrate was p-nitrophenylphosphate
(Sigma Chemical Co ., St . Louis, MO). Antibody activity was ex-
pressed as the absorbance at 405nm in a Titerteck Multiscan ELISA
reader (Flow Technologies, Inc., Phoenix, AZ). Anticardiolipin and
antitrinitrophenyl hapten (TNP) antibodies were similarlymeasured
by ELISAwith minor modifications as described previously (42, 43).
Histology.
￿
Organs were fixed in phosphate buffered 10% for-
malin (35mM phosphate, pH 7.0) and embedded in paraffin . Sec-
tions were stained with hematoxylin and eosin .
Results
Transgene Construct .
￿
BecausemMTI promoter is known
to be expressed andinducible in various organs such as liver,
kidney, intestine, heart, testis, muscle, brain, and spleen, we
used this promoter for expressing IL-5 (Fig . 1) . Murine 1175
cDNA that has no 3' untranslated region was inserted into
a part of rabbit (3-globin gene derived from pKCR vector
(44) and ligated to the mMTI promoter.
Production of1L5 Transgenic Mice .
￿
Two male mice (Nos .
3 and 6) were transgenic and were shown to carry about 5
or 40 copies of transgeneby Southern blot analysis, respec-
tively (Fig. 2 a) . Both founders transmitted transgenes to half
oftheir offspringwithoutregard to their sex. Although half
of the offspring ofmouse No . 3 integrated 11,5 transgene,
11,5 expression in terms of eosinophilia in peripheral blood
(see below) was very poor and variable among mice (-10%
eosinophils in hemizygote and <15% in homozygote even
in aged mice) . We therefore mainly analyzed IL5 transgenic
mice derived from No . 6 mouse in this study.
Thediscrimination betweenhemizygotes andhomozygotespOR327 mMT-I promoter
A
splice
donor
splice polyadenylatlon
acceptor site
Rabbit IL-5 Rabbit svw
P-globin cDNA P-globln
was possible by measuring the relative density of the 23-kb
band (endogenous IL5 gene) to the 5-kb band (transgene)
in the Southern blot described above (Fig. 2 b) . It was also
confirmed by the serum IgM level (Table 1) and the percentage
of eosinophils (Fig. 2 b and Table 2) in peripheral blood . In
No. 6 pedigree, all the individuals with 1175 transgene have
higher level of serum IgM (at least 1.5 times higher than
age-matched control) and >20% eosinophils in their periph-
eral blood .
Expression of the Mouse IL5 Gene in Transgenic Mice.
￿
To
Figure 2 .
￿
Detection of IIr5 transgene in the founder mouse and its descen-
dant by Southern blot analysis. Percentageofeosinophils in peripheral blood
of the individual mouse was also described . Eosinophils were identified
by staining the blood smears by May-Gruenwald and Giemsa solution .
(a) Among 13 offsprings, Nos . 3 and 6 were identified as founder trans-
genic mice. (b) Eight F2 mice derived from No . 6 were analyzed on the
ratio of two IIT5 genes (23 vs . 5 kb) by measuring the intensity of bands
in Southern blot .
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Figure 1 .
￿
Construct ofIIr5 transgene . SV40 promoter
of pKCR-mIlr5 was replaced with mMT I promoter as
described in Materials and Methods. The Xmnl-Nrul frag-
ment was injected into pronuclei of fertilized eggs of
C3H/HeN mice.
determine mRNA expression in IL5 transgenic mice, North-
ern blot analysis was performed using total RNA of liver
and spleen cells from cadmium-treated normal or IL-5 trans-
genic mice. Although both endogenous and transgene-derived
mRNA were of mouse origin, they were different in their
size. 11,5 mRNA from normal 116-producing hybridoma
B151K12 is 1.7 kb, as described (24), and the transgenic IL5
mRNA is 1.1 kb, as expected from L cells transfected with
pKCR-mMTI-mIL5 (the same construct used tomake trans-
genic mice) . The latter was probably caused by the removal
of the 3' untranslated region of IL-5 cDNA and the artificial
polyadenylation sites . Transcripts with the expected length
(1.1 kb) hybridizable with mouse IL-5 cDNA was detected
in RNA prepared from liver and spleen cells ofthe cadmium-
treated IL5 transgenic mice (Fig. 3) . Although the 1.1-kb
IL-5mRNA band was also detected in the RNA from spleen
and liver of IL-5 transgenic mice without cadmium adminis-
tration, its expression was low (data not shown) . We could
not detect either size of IL-5 mRNA in the RNA prepared
from spleen and liver cells ofcadmium-treated nontransgenic
mice under the conditions used in this study. IL-5 transgene
expression in liver was very variable, while that in spleen was
very constant among four mice of fourth generation .
The serum IL-5 level was determined by both biological
assay using the 11r5-dependent T88-M cells and ELISA as
described in Materials and Methods . Since we observed similar
results in both assay systems, we only described the data by
ELISA . The average serum IL-5 level in hemizygotes at 7wk
was 0.11 nit/ml, and that in homozygotes was 2.8 and 16.6
nit/ml at 7 and 25 wk of age, respectively (Table 1) . How-
ever, we could not found any IL5 activity in age-matched
control mice or in littermate mice (<0.01 nit/ml) . Thus,
serum IL-5 levels in these homozygous IL-5 transgenic mice
were estimated to be at least 1,600-fold higher than normal
level in 25-wk-old mice . By injecting cadmium sulfate solu-
tion into IL-5 transgenic mice, IL5 levels in their sera were
increased about fivefold within 24 h . These data clearly indi-
cated that the mouse IL5 transgene, which was inducible
upon stimulation with cadmium, was expressed constitutively
at least in liver and spleen . IL-5 transgene expression was also
observed in bone marrow and kidney (data not shown) .Table 1.
￿
Concentrations ofIL-5 and Serum Immunoglobulins of IL-5 Transgenic Mice
Figure 3 .
￿
Northern blot analysis of11,5 transgene expression after cad-
mium treatment . Individual mice (A, B, C, and D) were homozygotes
derived from No. 6 . 20 kg of total RNA was loaded into each well. B151Ki2
is a hybrid cell line producing a natural form of11,5 constitutively. pKCR-
mMTI-mIL5 is an L cell line transfected with this plasmid that has the
same construct with 11,5 transgene. Two lanes at the right hand side are
expressed in a decreased sensitivity ofBio-Analyzer 100 to make the bands
(1.1 and 1 .7 kb) clearer.
Results are expressed as the mean ± SE of five female mice in each group at 7 or 25 wk of age .
Data are measured in nanograms per milliliter .
t Data are measured in micrograms per milliliter .
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Female mice at the age of 25wk were surveyed for their peripheral blood cell populations. Smears of peripheral blood were stained with May-Gruenwald
and Giemsa solution, and their cell types were examined by microscope . The mean values and SE of five mice are shown in cell number per cubic millimeter .
Increase in Serum Immunoglobulin Levels and Eosinophih.
Serum immunoglobulin levels in these transgenic mice were
examined by ELISA. As shown in Table 1, the levels of serum
IgM and IgA were approximately eightfoldand fourfold higher
as compared with those of age-matched control mice that
were 7-wk-old, respectively. IgG1 and IgG2a were found to
be within control level . In 25-wk-old mice, IgM and IgA
levels in the sera of transgenic mice were -5- and 1.4-fold
higher than thoseof age-matchedcontrol mice, respectively.
Immunoglobulin levels of the sera of these transgenic mice
were not increased by the cadmium treatment .
The most striking feature of transgenic micewas a marked
increase in thenumber ofperipheral whiteblood cells (PBL),
of spleen cells, and of peritoneal cells . The total numbers of
PBL of hemizygous and homozygous transgenic mice were
-2.0 and -3.4 times higher than those in littermate control
mice, respectively (Table 2) . Particularly, the increase in the
number of eosinophils was at least 20-fold (hemizygote) to
70-fold (homozygote) compared with that of age-matched
control normal mice. Although the number of total lym-
Control mice
IL-5 transgenic mice derived from No . 6
(C3H/HeN) Hemizygotes Homozygotes
7 wk 25 wk 7 wk 7 wk 25 wk
Serum IL-5" <0.01 <0.01 0.11 ± 0.046 2 .8 ± 0.66 16.6 ± 13
Serum Igt
IgM 186 ± 3.3 293 ± 9.0 482 ± 38 1,524 ± 136 1,545 ± 261
IgG1 234 ± 16 736 ± 42 212 ± 12 256 ± 15 876 ± 26
IgG2a 397 ± 19 536 ± 24 375 ± 14 402 ± 23 512 ± 31
IgA 58 ± 8.5 216 ± 20 347 ± 17 229 ± 31 312 ± 11
Table 2. Peripheral Blood Cell Populations in IL-5 Transgenic vs. Control Mice
IL-5 transgenic mice
Cell type Control Hemizygotes Homozygotes
Total white blood cells 8,737 ± 578 17,333 ± 1156 29,800 ± 1682
Eosinophils 183 ± 62 5,175 ± 1087 13,719 ± 1024
Lymphocytes 5,757 ± 574 7,890 ± 520 10,365 ± 845
Monocytes 337 ± 119 468 ± 48 653 ± 60
Neutrophils 2,460 ± 766 3,800 ± 724 5,063 ± 189Figure 4.
￿
Increase of Ly-l' B cell population in 11,5 transgenic mice.
Scales are expressed in logio. Spleens of 25-wk-old 11,5 transgenic or age-
matched control mice were removed 5 d after the cadmium injection and
red blood cells were lysed . Total spleen cells were double stained with the
antibody combinations described (a and b) Ly-1 vs. 13220; (c and d) Ly-1
vs. IgM; (e andf) H7 vs . Ly-1. The cells in the lymphoid gate were ana-
lyzed by a flow cytometer. In all experiments, 20-fold class-matched Ig
was used to mask the Fc receptors (anti-Ly-2 mAb [56-6.72, rat IgG2a]
was used for rat IgG2a) . (a, c, and e) Control mice ; (b, d, and f) 11,5
transgenic mouse .
E
R
Figure 5 .
￿
Antigen binding of the IgM antibodies increased in the sera
of 11,5 transgenic mice. Open circles indicate the homozygotes for 11,5
transgene. Closed circles are hemizygotes . Open squares are age-matched
control mice. All samples were taken from 25-wk-old female mice.
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Figure 6 .
￿
Histology of IIr5 transgenic mice. (a) Spleen was fixed in
10% formalin and a section of it was stained with hematoxylin and eosin .
An eosinophil colony is indicated by an arrow. (b)A smear ofperipheral
blood was stained with May-Gruenwald and Giemsa solution (a, x 300 ;
b,
￿
x2000) .
phocytes and neutrophils were slightly increased in transgenic
mice, the numbers ofmonocytes were found to remain within
normal range. Peritoneal cavity ofthe littermate control mice
contained 2-6 x 106 cells. In contrast, there were as many
as 2.5 x 108 cells in the peritoneal cavity of transgenic mice
injected with cadmium . Without cadmium injection, 2-5
x 101 cells were found in the peritoneal cavity. About 50%
of those cells were eosinophils.
Increase in the Number ofLy-1 + and IL5Rpositive B Cells
in the Spleen of11,5 Transgenic Mice . We stained peritoneal
cells, spleen cells, and bone marrow cells from cadmium-
injected 116 transgenic mice or cadmium-injected control mice
with anti-Ly-1 mAb together with variousmAbs as described
in Materials and Methods. FRCS analysis revealed that propor-
tions of IL5R+ and Ly-1+ B cells of peritoneal cells from
IL-5 transgenic mice were unchanged compared with those
from littermate control (data not shown) . However, a dis-
tinctive Ly-ldun- and B220duu-positive population was
identified in the spleen cells of11,5 transgenic mice. Moreover,
this weakly Ly-1- and 13220-positive population was increased
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6 . Iin its number by the administration of cadmium into the
25-wk-old mice (Fig. 4, a vs . b) . Furthermore, this popula-
tion has higher density of IgM on its cell surface (Fig . 4,
c vs . d) . This Ly-1+ population also expresses IL-5R (H7 an-
tigen) (Fig. 4f) . These results suggest that in IL5 trans-
genic mice, ILSRpositive cells are selectively expanded and
some ofthem also coexpress Ly-1 antigens simultaneously.
No difference in the ratio of CD4+ over CD8+ or of
CZ/0+ over ,y/S+ was observed among T lymphocytes, and
we could not find any increase in allo-killer orMLR activity
in IL5 transgenic mice (data not shown) .
Autoantibody Production in 11,5 Transgenic Mice
￿
The in-
crease in the total number of Ly-1+ and IL5R+ B cells in
the peritoneal cavity and the spleen in IL5 transgenic mice
prompted us to examine the production of autoantibodies
in the transgenic mice, because Ly-1+ B cells are supposed
to produce autoantibodies (45-47) . To examine the levels of
autoantibodies, we adopted ssDNA, dsDNA, and cardiolipin
as test antigens . As a control antigen, TNP was also used .
As shown in Fig . 5, we could detect IgM autoantibodies
against each antigen in the sera of all 11,5 transgenic mice
(six mice are hemizygotes and four mice were homozygote),
although the titer in each mouse was variable . These sera
reacted also to TNP, and antibody activity to each antigen
was absorbed by ssDNA or dsDNAcoupled Sepharose beads
(data not shown), indicating that autoantibodies are poly-
reactive . No anti-DNA antibodies were found in IgA or IgG
fraction (data not shown) .
Pathological Findings in Tissues of11,5 Transgenic Mice.
￿
To
examine the pathological changes in the IL5 transgenic mice,
two homozygous transgenic mice were killed at 20-25 wk
of age. The other two homozygous transgenic mice, which
had received four consecutive intraperitoneal injections ofcad-
mium on days 19, 14, 10, and 5 before death, were also sub-
jected to pathological examination . Aftercadmium treatment,
the spleen was enlarged (about five times in cell number) and
had white patches consisting of the mass of eosinophils. All
the specimens shown in Fig. 6 are from cadmium-injected
mice. Both ofthem showed splenomegaly, and no detectable
lymph node enlargement . In the spleen, eosinophils were seen
in the marginal area and some of them form colony-like
proliferations (indicated by an arrow) all over the spleens (Fig .
6 a) . Erythroblasts and megakaryocytes were seen more fre-
quently than in normal spleen . Eosinophils were rarely seen
in normal spleen cells . Large parts of bone marrow were oc-
cupied by mature or immature eosinophils. In the liver, infiltra-
tion of eosinophils was mainly observed in Glisson's capsule,
and slightly in lobes. Eosinophil infiltration was also seen
in the muscle, and derangement of sarcolemma and disap-
pearance of striation were observed . Moreover, we also ob-
served mass of eosinophils along connective or fat tissue sor-
rounding muscle. In both cases there was infiltration of
eosinophils with ring- or U-shaped nuclei and cytoplasm full
of red granules. The typical eosinophils seen in peripheral
blood of IL5 transgenic mice were shown in Fig. 6 b . The
nuclei of eosinophils were found most frequently as a ring-
shaped structure, which sometimes showed a folded "figure-
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eight" structure . The ring form was always an even-sized band
(Fig. 6 b) . Although the mouse neutrophils also had ring-
shaped nuclei, they were frequently lobulated . The cytoplasm
of eosinophils was filled with small, acidophilic granules which
were even in their size . In contrast, the granules of mouse
neutrophils were stained poorly and mouse neutrophils ap-
peared to lack cytoplasmic granules.
Discussion
In this study, we describe the generation of a massive eo-
sinophilia and production of polyreactive autoantibodies in
IL-5 transgenic mice in which mouse IL5 cDNA is constitu-
tively expressed. This eosinophilia is characterized as follows :
(a) the presence of eosinophils with mitosis in spleen, bone
marrow, and liver ; (b) infiltration of many organs with eo-
sinophils, including liver, muscle, heart, lymph node along
the bronchus, and Peyer's patches ; eosinophils have a tendency
to lodge around the connective tissue such as marginal area
of spleen, liver, Peyer's patches, and between muscle and fat
tissue . Eosinophils probably have some affinity to the certain
matrix in connective tissue . In case of muscle, it might be
a sign of myositis or fascitis. This feature reminds us of
Shulman's disease (48) ; (c) the presence ofmassive eosinophils
in peripheral blood . All these data suggest that IL5 trans-
genic mouse can be a model of idiopathic hypereosinophilic
syndrome (49) . Especially, hypereosinophilic syndrome in-
duced by a graft-vs .-host reaction appears to be caused by
1175, because IL5 isknown to be produced in a large amount
by alloreactive T cells (49, 7) .
It is reasonable to expect that in IL5 transgenic mice, the
totalnumber of IL5R-positive B cells are increased . We also
asked if Ly-1 + B cells are increased or not in these transgenic
mice, because we observed high incidence of Ly-1+ early B
cells in the long-term bone marrow culture on the stromal
cells in the presence ofIL5 (26, 50) . We used mAb H7 (38,
39) against IL5R to analyze numbers and distribution of
11,5R-positive cells. In normal mice, most peritoneal sur-
face IgM+ B cells were IL5R positive, and >70% of 11,5R-
positiveB cells express Ly-1 antigens on their cell surface (39) .
On the contrary, only small populations of splenic B cells
are H71°» positive, and the H7duu and Ly-1 double-positive
cells are marginal (39) .
Ly-1 + B cells are a distinct minor subpopulation of B cells
and have numerous noteworthy characteristics (for reviews
see references 27, 28, 51, 52), such as self-replenishing ac-
tivity (53-55), particular tissue distribution (abundant in the
peritoneal cavity) (46, 53), and production of autoantibodies
(45-47) . Furthermore, functional studies have suggested that
Ly-1+ B cells are selected for the expression of a restricted
repertoire of antibody specificities (52, 56) . These are the major
reasons why Ly-1+ B cells have been considered to be of a
separate B cell lineage.
In IL5 transgenic mice, Ly-1+ B cell population is not rel-
atively increased in peritoneal lymhocytes. In the spleen, how-
ever, B220 and Ly-lduu-positive B cells were dramatically in-
creased and many of them were surface IgM and H7 positive.Ly-1 density on their cell surface seems to be lower than those
on peritoneal cells of normal littermate . This distinctive
Ly-1+ and B220+ population was also seen in the bone
marrow cells, though it was not as clear as in the spleen .
This less extensive domination of weakly Ly-1+ and B220+
populations in the bone marrow may partly be explained by
the occupation of medullary cavity by eosinophils. This in-
crease in the number of Ly-1+ B cells and eosinophils could
be waned by intraperitoneal injection of anti-IL-5 antibody
(data not shown) .
Mechanism of the preferential increase of Ly-1 + B cell
population in the spleen of IL-5 transgenic mice is not fully
understood, but direct involvement of11,5 is highly possible .
In vitro growth of Ly-1 + pre-B cells and chronic B cell
leukemia cells were shown to depend on 11,5 (4, 7, 14) . Re-
cently, we established earlyB lineage cell lines dependent on
stromal cell line ST2 and IIr5 by using Whitlock-Witte type
bone marrow culture system . Surprisingly, all 18 clones we
established were Ly-1+, while early B lineage cells estab-
lished in the absence of 11,5 at the same time are rarely
Ly-1 + (26, 50) . We also presented evidence that bone
marrow cells from 3-wk-old mice contains Ly-1 + B cell
precursors and these cells could be selectively maintained in
the presence of IL-5 and bone marrow-derived stromal cells
(50) . By culturing bone marrow cells either from 8- or
3-wk-old 1175 transgenic mice, we found the generation of
IL5-responsive Ly-1+ cells even in the absence of 116, sug-
gesting that Ly-1 + B cells may well be maintained in bone
marrow of adult IL-5 transgenic mice. However, we could
not observe the fully mature Ly-1 + B cells in this in vitro
culture system, although they become pre-B cells expressing
2.7-kb membrane type it mRNA (50) . This I1,5 transgenic
mouse confirmed the involvement ofIL-5 in the development
of Ly1+ B cells in vivo.
The findings described in this study indicate the essential
role of deregulated production of IL-5 in eosinophilia and
preferential growth of Ly-1 + B cells that resulted in the in-
crease in total numbers of Ly-1 + B cells in the spleen . IL5
is probably involved in the production of polyreactive IgM
antibodies in IIr5 transgenic mice, because similar polyreac-
tiveIgM autoantibodies containing anti-DNA activity could
be elicited by the intraperitoneal injection of 1 hg pure IL-5
(data not shown) . However, we do not have direct evidence
indicating polyreactive anti-DNA antibodies are produced by
Ly-1 + B cells. It is very unlikely that polyreactive anti-DNA
antibodies are produced only by Ly-1 + B cells, because there
are significant amounts B cells that do not express Ly-1 an-
tigen but express IL-5 receptors .
The fact that those polyreactive anti-DNA antibodies can
be recovered from aDNA Sepharose column with 0.5M NaCl
at neutralpH suggests that the antigenic determinant recog-
nized by these autoantibodies is the conformational struc-
ture (43) . This trait ofanti-DNA antibodies is shared with
the naturally occurring anti-DNA antibodies in patients with
SLE or in lupus model mice (43) .
The relation of these polyreactive autoantibodies to au-
toimmunity is unknown . It is suggested that the class switch
of these autoantibodies from IgM to IgG may cause lupus
(57) . We introduced our IL5 transgene into mice having
genetic backgrounds that facilitate the progression ofautoim-
munity, such as MRL/lpr or NZW by mating, but so far,
no such class switch was observed . Continuous expression
of IL-5 might be rather inhibitory for the outbreak of the
disease. It might be expressed transiently before the onset
of lupus . We are currently trying to induce IL5 transgenic
mice to make a class switch from IgM to IgG.
In general, these polyreactive autoantibodies are known
as naturally occurring antibodies in normal serum and are
believed to be engaged in the primary protection against in-
fection of microorganisms (27, 28, 53, 58) . On the other
hand, eosinophils are also believed to be involved in the pro-
tection against parasites, and 11,5 is known to be induced
when mice are infected with parasites (25, 59) . Taken together,
IL-5 seems to engage in the primary defense mechanism against
the infection of parasites and microorganisms. We are cur-
rently investigating if these mice are really resistant against
the infection of microorganisms.
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